Abstract
An in vivo bromodeoxyuridine (BrdU) labeling index (LI) was estimated in 43 cases of astrocytic tumors and mixed gliomas by one hour intra-opera-tive intravenous infusion at a dose of 200 mg/m2 and correlated with (a) histological grading using a computer aided malignancy classifier TESTAST-268; and (b) histological typing using WHO classification. The lowest BrdU LI was seen in pilocytic and gemistocytic astrocytomas followed by astrocytomas, anaplastic astrocytomas and glioblastoma multi-forme in that order. Mixed oligoastrocytomas followed the pattern of their astrocytic counterparts. Tumors of similar histological type showed different BrdU LI values especially amongst astrocytomas and glioblastomas. A statistically significant difference in the BrdU LI was also noted between the higher TESTAST grades of astrocytomas (T III and IV) versus the lower TESTAST grades (T II). Unlike earlier reports in literature, in the present study the category of BrdU LI of <1 contained no case of anaplastic astrocytoma or glioblastoma multiforme (TESTAST grades III and IV). Likewise, the category of BrdU LI >5 contained only anaplastic astrocytoma and glioblastoma multiforme (TESTAST grades III and IV). Maximum spread of cases was seen in the BrdU LI category of 1–5, not only in terms of histological types but also TESTAST grades. Thus there appeared to be a positive trend of increasing BrdU LI values both with histological types and increasing TESTAST grades. Further, an interesting observation was that by using a combination of TESTAST grades and BrdU LI, the histologically homogenous glioblastoma group could be further subdivided into 4 categories which showed a trend towards prognostic correlation. Thus, this study though preliminary with number of cases being small in some groups, highlights the possible usefulness of combined histological typing, TESTAST grading and in vivo BrdU LI for prognostication of gliomas especially glioblastoma multiforme.
Similar content being viewed by others
References
Burger PC,Scheithauer BW: Tumors of the central nervous system. Armed Forces Institute of Pathology, Washington, 1994.
Burger PC, Vogel FS, Green SB, et al: Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 56:1106–1111, 1985.
Daumos-Duport C, Scheithauer B, OF allen J, et al: Grading of astrocytomas: A simple and reproducible method. Cancer 62:2152–2165, 1988.
Dinda AK, Kharbanda K, Sarkar C, et al: In-vivo proliferative potential of primary human brain tumors: Its correlation with histological classification and morphological features. I. Gliomas. Pathology 25:4–9, 1993.
Dinda AK Kharbanda K, Sarkar C, et al: In-vivo proliferative potential of primary human brain tumors: Its correlation with histological classification and morphological features. II. Nonglial Tumors. Pathology 25:10–14, 1993.
Gilles FH, Leviton A, Hedley-Whyte ET, et al: Childhood braintumor update. Hum Pathol 14:834–845, 1983.
Gol A: The relative benign astrocytomas of cerebrum: A clinical study of 194 verified cases. J Neurosurg 18:501–506, 1961.
Hoshino T: A commentary on biology and growth kinetics of low grade and high grade gliomas. J Neurosurg 61:895–900, 1994.
Hoshino T, Nagashima T, Murovic JA, et al: In situ cell kinetic studies on human neuroectodermal tumors with bromod-eoxyuridine labeling. J Neurosurg 64:453–59, 1986.
Hoshino T, Prados M, Wilson CB, et al: Prognostic implications of low bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71:335–341, 1989.
Hoshino T, Rodriguez LA, Cho KC, et al: Prognostic implications of the proliferative potential of low grade astrocytomas. J Neurosurg 69:839–1342, 1988.
Hoshino T, Townsend JJ, Muraoka I, et al: An autoradiograph-ic study of human gliomas: growth kinetics of anaplastic astrocytomas and glioblastoma multiforme. Brain 103:967–984, 1980.
Hoshino T, Wilson CB: Review of basic concepts of cell kinetics as applied to brain tumors. J Neurosurg 42:123–131, 1975.
Hoshino T, Wilson CB: Cell kinetic analysis of human malignant brain tumors (gliomas). Cancer 44:956–962, 1979.
Kernohan JW, Mabon RF, Svien HJ, et al: A simplified classification of gliomas. Proc Staff Meet Mayo Clin 24:71–75, 1949.
Kernohan JW, Sayre GP: Tumors of Central Nervous System. Fascicle 35, Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington, p17–129, 1952.
Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. International classification of tumors. 2nd ed. World Health Organisation. Springer Verlag, Berlin, 1993.
Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 7:755–764, 1997.
Morimura T, Kitz K, Budka H: In situ cell kinetics in human brain tumors. A comparative immunocytochemical study of Sphase cells by a new in vitro bromodeoxyuridine labeling technique and of proliferating pool cells by monocolonal antibody Ki-67. Acta Neuropathol 77:276–282, 1989.
Murovic JA, Nagashima T, Hoshino T, et al: Pediatric central nervous system tumors: A cell kinetic study with bromodeoxyuridine. Neurosurg 19:900–904, 1986.
Nagashima T, DeArmond SJ, Murovic J, et al: Immunocytochemical demonstration of S-phase cells by anti-bromodeoxyuri-dine monoclonal antibody in human brain tissues. Acta Neuropathol 67:155–159, 1985.
Nelson JS, Tuskada Y, Schoenfeld D, et al: Necrosis as a prognostic criteria in malignant supratentorial astrocytic gliomas. Cancer 52:550–554, 1983.
Ringertz J: Grading of gliomas. Acta Pathol Microbiol Scand 27:51–64, 1950.
Russell DS,Rubinstein LJ: Tumors of central neuroepithelial origin. In: Pathology of tumors of the Nervous System. Edward Arnold, London, 198; p 83–247.
Scanlon PW, Taylor WF: Radiotherapy of intracranial astrocytomas. Analysis of 417 cases treated from 1960 through 1969. Cancer 5:301–307, 1979.
Schmitt HP: Numerical classification of malignancy in astrocytomas: An attempt to improve and to validate the classifier TESTAST. Studien Zur Klassifikation. Indek Verlag, Frankfurt, p361–368, 1989.
Schmitt HP, Oberwittler C: Computer aided classification of malignancy in astrocytomas: II. The value of categorically evaluating histologic and non-histologic features for a numerical classifier. Analyt Cell Pathol 4:409–419, 1992.
Schmitt HP, Oberwittler C, Schad LR: Computer aided classification of malignancy in astrocytomas: I. The value of nuclear parameters obtained by automated black and white image analysis. Analyt Cell Pathol 4:397–407, 1992.
Sharma S, Karak AK, Sarkar C, et al: A grading study of glio-mas using histologic morphometry and malignancy classification. J Neuro-Oncol 27:75–85, 1996.
Shapiro JR: Biology of gliomas: heterogenity, oncogenes, growth factors. Semin Oncol 133:4–15, 1986.
Watanabe K, Tachibona O, Yonekawa Y, et al: Role of gemisto-cytes in astrocytoma progression. Lab Inv 76:277–284, 1977.
Wier B: The relative significance of factors affecting post-operative survival in astrocytoma grade III and IV. J Neurosurg 38:448–452, 1973.
Wier B, Grace M: The relative significance of factors affecting operative survival in astrocytomas, grades I and II. Can J Neurol Sci 33:47–50, 1976.
Zulch KJ: Histological typing of tumors of central nervous system. International Histologic Classification of Tumors. World Health Organisation, Geneva, p 14–50, 1979.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sharma, S., Karak, A.K., Singh, R. et al. A correlative study of gliomas usingIn vivo bromodeoxyuridine labeling index and computer-aided malignancy grading. Pathol. Oncol. Res. 5, 134–141 (1999). https://doi.org/10.1053/paor.1999.0189
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1053/paor.1999.0189